DNA Testing Firm Spirals by 45%

A much-touted DNA testing firm is spiraling after filing for bankruptcy; a lunar tech firm is gaining momentum after a historic Moon landing and strong revenue growth; and a tiny biotech firm is soaring after a new licensing deal. Here’s what you need to know.

Crypto (Sponsored)

Gemini: Where America buys, sells, and stores bitcoin and 70+ other cryptocurrencies

Gemini is a fully licensed and regulated exchange that makes buying and selling cryptocurrency safe and easy in all 50 US States.

Discover why Investopedia recently awarded Gemini “Best For Security” and “Best for Experienced Traders.”

Head over to Gemini and start trading to earn $20 in BTC.

Get $20 in bitcoin.

Futures 📈

What to Watch

Earnings:

• KB Home [KBH]: Aftermarket

• Oklo Inc. [OKLO]: Aftermarket

• Enerpac Tool Group Corp. [EPAC]: Aftermarket

• D-Market Electronic Services & Trading [HEPS]: Aftermarket

Economic Reports:

• S&P flash U.S. services and manufacturing PMI: 9:45 a.m.

Future of Screen Tech (Sponsored)

This Display Stock Could Be the Next OLED

The rise of OLED technology created life-changing returns for early investors—turning a $6 IPO into a $252 stock. Now, a new wave is forming in display tech, and it could be even bigger.

The MicroLED market is projected to surge past $21 billion by 2027, with a CAGR of over 80%.

One small company is leading the charge with a patented, cost-effective production process that could finally make MicroLED displays scalable—and profitable.

With a co-development partnership in place and growing industry momentum, this stock could be the one to watch before Wall Street catches on.

Get the name and full report here.

DNA Testing

23andMe Files for Bankruptcy After Data Breach and Declining Sales

Genetic testing company 23andMe (NASDAQ: ME) has filed for bankruptcy in the United States and is now seeking a buyer, marking a dramatic fall from its once high-flying status.

The move comes after the company grappled with a major data breach, plummeting demand for its DNA kits, and unsuccessful efforts to secure a takeover.

On Sunday, the company submitted its Chapter 11 filing, listing estimated liabilities between $100 million and $500 million.

It also announced it has secured a $35 million financing commitment to maintain operations during the restructuring process.

Shares are down 45% in early trade following the resignation of co-founder and CEO Anne Wojcicki.

Chief Financial Officer Joe Selsavage has been named interim CEO. Wojcicki’s multiple buyout proposals—including a recent bid valuing the company at just $11 million—were reportedly rejected by the board.

The company is currently valued at approximately $50 million, far below its 2021 peak of $6 billion when it went public via a SPAC led by Richard Branson.

A 2023 cyberattack that compromised data from 7 million users dealt a significant blow to 23andMe’s credibility.

The firm later agreed to a $30 million settlement and cut 200 jobs. All therapeutic development was also halted last year.

Wojcicki signaled on X that she plans to make another offer to acquire the company, though no further details have been shared.

Space Technology

Intuitive Machines Posts Strong Q4 and Full-Year Growth Following Historic Lunar Mission

Lunar exploration and space technologies firm Intuitive Machines (NASDAQ: LUNR) posted a strong finish to 2024, with fourth-quarter revenue rising 79% year-over-year to $54.7 million.

For the full year, the company generated $228 million in revenue—nearly triple its 2023 total.

In a standout achievement, the company successfully completed the southernmost lunar landing in history, enhancing its credibility.

Technical advancements and new contracts with NASA also contributed to its growth momentum.

Shares of the firm are up 2.6% in premarket trading.

Intuitive Machines closed 2024 with $207.6 million in cash, which has since grown to $385 million by March 2025 following a warrant redemption and a $125 million equity raise through a private placement with Boryung.

Its backlog climbed 22% year-over-year to $328.3 million.

The company recorded positive gross margins in back-to-back quarters for the first time and now forecasts 2025 revenue between $250 million and $300 million.

Management expects to hit positive run-rate adjusted EBITDA by the end of this year, with full-year profitability projected in 2026.

AI (Sponsored)

The AI Energy Miracle

All the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can.

Three Companies Set to See Enormous Profit Potential.

Details Here.

Data Analytics

DNB to Be Acquired by Clearlake Capital in $7.7 Billion Deal

Dun & Bradstreet (NYSE: DNB) has officially announced an agreement to be acquired by Clearlake Capital Group in a transaction valued at $7.7 billion, including the assumption of debt.

The deal places the company’s equity value at $4.1 billion, with shareholders set to receive $9.15 in cash per share.

The move marks a major shift for the business data and analytics provider, which is set to transition back into a privately held company following the completion of the transaction.

The deal includes a 30-day “go-shop” period, allowing Dun & Bradstreet to solicit alternative offers.

The acquisition is expected to close in the third quarter of 2025, pending shareholder approval and regulatory clearance.

Over the past six years, Dun & Bradstreet has reported steady operational improvements, with revenue increasing by 40% and EBITDA up by 60%.

The company has also expanded its profit margins by nearly 600 basis points and lowered its leverage ratio from 9x to 3.6x.

The buyout by Clearlake Capital reflects continued interest from private equity firms in acquiring established enterprise data providers, particularly those with improved profitability and reduced debt loads.

Once finalized, Dun & Bradstreet will be removed from public markets and begin a new chapter under private ownership.

Windtree Therapeutics, Inc. [WINT] - Last Close: $1.48

Windtree Therapeutics is a biotechnology company traditionally focused on cardiovascular therapies.

Shares of the firm are soaring 37% in premarket trading after it entered a licensing and sourcing deal with Evofem Biosciences to manufacture Phexxi, a non-hormonal birth control vaginal gel, at lower cost.

Diginex Limited [DGNX] - Last Close: $110.00

Diginex is an ESG-focused regulatory technology (RegTech) firm which provides digital solutions for sustainable finance and compliance.

Shares of the Diginex are rising 11% in early trading because the company announced a major strategic partnership with His Highness Shaikh Mohammed Bin Sultan Bin Hamdan Al Nahyan of the Abu Dhabi Royal Family.

The deal includes a $250 million capital injection and a planned dual listing on the Abu Dhabi Securities Exchange (ADX).

The AZEK Company Inc. [AZEK] - Last Close: $41.39

The AZEK Company specializes in low-maintenance, sustainable outdoor living products like decking, trim, and railings.

Shares of the firm are surging in premarket trading after James Hardie Industries announced an $8.75 billion cash-and-stock deal to acquire it.

The offer values AZEK at $56.88 per share, a 26% premium to its recent average price.

What’s Musk Planning? (Sponsored)

“A Maniacal Sense of Urgency”

A Boston based think tank believes we could be just days away from Elon Musk launching his next big venture.

It’s uniquely connected to his new role in the Department of Government Efficiency ("DOGE")… but could have a far reaching impact on every facet of life in America.

They’ve released a fascinating new documentary connecting all the dots on what they believe Elon’s planning and how it could impact your money.

Get the details here.

Everything Else

• Ant Group claims an AI breakthrough using Chinese chips to cut training costs.

• Tesla’s FSD rollout in China was delayed due to new autonomous driving rules.

• AstraZeneca strengthens its China ties with a Beijing hub as regulatory challenges persist.

• Supermicro leads S&P 500 gains as analysts see growth potential in AI servers.

• Carnival Corp beats profit estimates as travel demand boosts revenue.

• Miniso’s stock struggles as quarterly earnings fall short of forecasts.

• American Express raises its dividend and share buybacks amid strong financial performance.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.

*Standard message/carrier rates may apply.

Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.